Works matching IS 00223417 AND DT 2020 AND VI 250 AND IP 1


Results: 13
    1
    2
    3

    Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer.

    Published in:
    Journal of Pathology, 2020, v. 250, n. 1, p. 19, doi. 10.1002/path.5344
    By:
    • Alborelli, Ilaria;
    • Leonards, Katharina;
    • Rothschild, Sacha I;
    • Leuenberger, Laura P;
    • Savic Prince, Spasenija;
    • Mertz, Kirsten D;
    • Poechtrager, Severin;
    • Buess, Martin;
    • Zippelius, Alfred;
    • Läubli, Heinz;
    • Haegele, Jasmin;
    • Tolnay, Markus;
    • Bubendorf, Lukas;
    • Quagliata, Luca;
    • Jermann, Philip
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Issue Information.

    Published in:
    Journal of Pathology, 2020, v. 250, n. 1, p. 1, doi. 10.1002/path.5293
    Publication type:
    Article